Hit by 2 more flops, Bris­tol My­ers and Nek­tar wind down IL-2/PD-1 pro­gram at the cen­ter of $3.6B deal

Four years af­ter Bris­tol My­ers Squibb paid a record-break­ing $1.85 bil­lion in cash to part­ner with Nek­tar Ther­a­peu­tics and launch a sprawl­ing clin­i­cal pro­gram to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER